Evidence map›Paper›PMID 39302125›Full record

ArticlemBio2024

SARS-CoV-2 infection induces hyaluronan production

Urban Hellman, Ebba Rosendal, Joakim Lehrstrand, Johan Henriksson, Tove Björsell, Alfred Wennemo, Max Hahn, Björn Österberg, Luiza Dorofte, Emma Nilsson and 12 more

Abstract read
In one paragraph

Article in mBio, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors.

Urban HellmanDepartment of Clinical Microbiology, Umeå University, Umeå, Sweden.
Ebba RosendalDepartment of Clinical Microbiology, Umeå University, Umeå, Sweden.
Joakim LehrstrandUmeå Centre for Molecular Medicine (UCMM), Umeå University, Umeå, Sweden.
Johan HenrikssonThe Laboratory for Molecular Infection Medicine Sweden (MIMS), Umeå University, Umeå, Sweden.
Tove BjörsellCentre for Clinical Research and Education, Region Värmland, Karlstad, Sweden.
Alfred WennemoDepartment of Clinical Microbiology, Umeå University, Umeå, Sweden.
Max HahnUmeå Centre for Molecular Medicine (UCMM), Umeå University, Umeå, Sweden.
Björn ÖsterbergDivision of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Luiza DorofteDepartment of Laboratory Medicine, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Emma NilssonDepartment of Clinical Microbiology, Umeå University, Umeå, Sweden.
Mattias N E ForsellDepartment of Clinical Microbiology, Umeå University, Umeå, Sweden.ORCID 0000-0001-6904-742X
Anna Smed-SörensenDivision of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Anna LangeDepartment of Infectious Diseases, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Mats G KarlssonDepartment of Laboratory Medicine, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Clas AhlmDepartment of Clinical Microbiology, Umeå University, Umeå, Sweden.
Anders BlombergDepartment of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
Sara CajanderDepartment of Infectious Diseases, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Ulf AhlgrenUmeå Centre for Molecular Medicine (UCMM), Umeå University, Umeå, Sweden.
Alicia LindDepartment of Surgical and Perioperative Sciences, Umeå University, Umeå, Sweden.
Johan NormarkDepartment of Clinical Microbiology, Umeå University, Umeå, Sweden.
Anna K Överby *Department of Clinical Microbiology, Umeå University, Umeå, Sweden.ORCID 0000-0001-6553-0940
Annasara Lenman *Department of Clinical Microbiology, Umeå University, Umeå, Sweden.ORCID 0000-0001-5109-9408

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We previously demonstrated that the lungs of deceased COVID-19 patients were filled with a clear hydrogel consisting of hyaluronan (HA). In this translational study, we investigated the role of HA at all stages of COVID-19 disease to map the consequences of elevated HA on morbidity and identify the mechanism of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced HA production. A reduced alveolar surface area was observed in the lungs of deceased COVID-19 patients compared to healthy controls, as visualized by a 3D rendering of lung morphology using light-sheet fluorescence microscopy. We confirmed the presence of HA in lung biopsies and found large quantities of proinflammatory fragmented HA. The association of systemic HA in blood plasma and disease severity was assessed in patients with mild (WHO Clinical Progression Scale, WHO-CPS, 1-5) and severe COVID-19 (WHO-CPS, 6-9) during the acute and convalescent phases and related to lung function. We found that systemic levels of HA were high during acute COVID-19 disease, remained elevated during convalescence, and were associated with a reduced diffusion capacity.

Indexed as

COVID-19Hyaluronic AcidLungSARS-CoV-2AdultAgedFemaleHumansMaleMiddle AgedProspective StudiesSeverity of Illness IndexHyaluronic Acid3D-lung modelCOVID-19hyaluronanhyaluronic acidlung impairmentSARS-CoV-2

Identifiers

PMID39302125
PMCPMC11492986

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.